Press Review from 20/01/09 to the 22/01/09
In 2008, Abbott earned $5 billion
(International Herald Tribune: p. 13, The Wall Street Journal online, Les Echos online - January 22, 2009)
Abbott closed 2008 on a positive note: net income increased by 35% to $4.8 billion and turnover increased by 13.9% to $29.5 billion. In the 4th quarter, net income increased 28%, driven primarily by sales of arthritis drug Humira (adalimumab). For 2009, Abbott estimates earnings per share of between $3.35 and $3.70.
http://www.aboutpharma.it/
EU: Roche's drug for rheumatoid arthritis approved
(The Wall Street Journal online - January 22, 2009)
The European Union has approved the marketing of RoActemra (tocilizumab), a drug for the treatment of rheumatoid arthritis co-developed by Roche and its Japanese subsidiary Chugai. The medicine will be combined with another drug in adult patients who are unresponsive or intolerant to other therapies.
http://www.aboutpharma.it/
US: 635 million dollars to eradicate polio
(The Wall Street Journal
